Latest Insider Transactions at Merck & Co., Inc. (MRK)
This section provides a real-time view of insider transactions for Merck & Co., Inc. (MRK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Merck & Co., Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Merck & Co., Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 01
2021
|
Caroline Litchfield EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
288
-1.51%
|
$21,312
$74.5 P/Share
|
|
May 01
2021
|
Caroline Litchfield EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
840
+4.22%
|
$62,160
$74.5 P/Share
|
|
May 01
2021
|
Lisa Le Cointe Cephas SVP Chief Ethics & Com Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
210
-11.41%
|
$15,540
$74.5 P/Share
|
|
May 01
2021
|
Lisa Le Cointe Cephas SVP Chief Ethics & Com Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
622
+25.25%
|
$46,028
$74.5 P/Share
|
|
Feb 26
2021
|
Kenneth C Frazier Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
175,249
+23.0%
|
$12,617,928
$72.62 P/Share
|
|
Feb 26
2021
|
Michael Fleming SVP Chief Ethics & Com Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,437
+25.05%
|
$247,464
$72.62 P/Share
|
|
Feb 26
2021
|
Michael Nally EVP, Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,127
+26.64%
|
$513,144
$72.62 P/Share
|
|
Feb 26
2021
|
Frank Clyburn EVP & Pres ? Human Health |
BUY
Grant, award, or other acquisition
|
Direct |
9,432
+9.25%
|
$679,104
$72.62 P/Share
|
|
Feb 26
2021
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
BUY
Grant, award, or other acquisition
|
Direct |
25,772
+21.67%
|
$1,855,584
$72.62 P/Share
|
|
Feb 26
2021
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,585
+24.32%
|
$906,120
$72.62 P/Share
|
|
Feb 26
2021
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Grant, award, or other acquisition
|
Direct |
25,510
+18.28%
|
$1,836,720
$72.62 P/Share
|
|
Feb 26
2021
|
Robert M Davis Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
46,641
+17.64%
|
$3,358,152
$72.62 P/Share
|
|
Feb 26
2021
|
Jennifer Zachary EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
24,199
+43.88%
|
$1,742,328
$72.62 P/Share
|
|
Feb 26
2021
|
Steven Mizell EVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,830
+43.48%
|
$1,283,760
$72.62 P/Share
|
|
Feb 26
2021
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Grant, award, or other acquisition
|
Direct |
6,052
+15.17%
|
$435,744
$72.62 P/Share
|
|
Feb 26
2021
|
David Michael Williams EVP,Chief Info&Digital Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,090
+31.32%
|
$150,480
$72.62 P/Share
|
|
Feb 26
2021
|
Dean Y Li Executive VP & President, MRL |
BUY
Grant, award, or other acquisition
|
Direct |
3,485
+24.65%
|
$250,920
$72.62 P/Share
|
|
Feb 10
2021
|
David Michael Williams EVP,Chief Info&Digital Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
467
-12.76%
|
$35,025
$75.04 P/Share
|
|
Feb 10
2021
|
David Michael Williams EVP,Chief Info&Digital Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,167
+24.18%
|
$87,525
$75.04 P/Share
|
|
Nov 09
2020
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
280,000
-22.79%
|
$22,680,000
$81.41 P/Share
|
|
Oct 30
2020
|
Steven Mizell EVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,273
-29.81%
|
$170,475
$75.89 P/Share
|
|
Oct 30
2020
|
Steven Mizell EVP, Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,574
+37.5%
|
$343,050
$75.89 P/Share
|
|
Oct 30
2020
|
Michael Nally EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
995
-7.42%
|
$74,625
$75.89 P/Share
|
|
Oct 30
2020
|
Michael Nally EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,287
+14.58%
|
$171,525
$75.89 P/Share
|
|
Oct 30
2020
|
Frank Clyburn EVP & Pres ? Human Health |
SELL
Payment of exercise price or tax liability
|
Direct |
1,137
-1.36%
|
$85,275
$75.89 P/Share
|
|
Oct 30
2020
|
Frank Clyburn EVP & Pres ? Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
2,287
+2.66%
|
$171,525
$75.89 P/Share
|
|
Oct 05
2020
|
Robert M Davis Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
251,273
-59.5%
|
$20,353,113
$81.03 P/Share
|
|
Oct 05
2020
|
Robert M Davis Chairman, CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
251,273
+37.3%
|
-
|
|
Aug 13
2020
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
SELL
Open market or private sale
|
Direct |
10,380
-13.35%
|
$861,540
$83.01 P/Share
|
|
Aug 05
2020
|
Frank Clyburn EVP & Pres ? Human Health |
SELL
Open market or private sale
|
Direct |
18,876
-18.94%
|
$1,528,956
$81.55 P/Share
|
|
Aug 05
2020
|
Frank Clyburn EVP & Pres ? Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
18,876
+15.93%
|
-
|
|
Jul 17
2020
|
Julie L. Gerberding EVP, Chief Patient Officer |
SELL
Open market or private sale
|
Direct |
36,285
-34.71%
|
$2,902,800
$80.01 P/Share
|
|
Jul 17
2020
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,111
+22.37%
|
-
|
|
May 07
2020
|
Leslie A Brun Director |
SELL
Open market or private sale
|
Direct |
5,000
-71.96%
|
$375,000
$75.46 P/Share
|
|
May 07
2020
|
Leslie A Brun Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+41.85%
|
-
|
|
May 07
2020
|
Wendell P Weeks Director |
SELL
Open market or private sale
|
Direct |
5,000
-98.04%
|
$380,000
$76.02 P/Share
|
|
May 07
2020
|
Wendell P Weeks Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+49.51%
|
-
|
|
May 05
2020
|
Michael Nally EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,020
-8.46%
|
$77,520
$76.86 P/Share
|
|
May 05
2020
|
Michael Nally EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,345
+16.29%
|
$178,220
$76.86 P/Share
|
|
May 05
2020
|
Rita A Karachun Sr. VP Fince-Global Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
1,617
-5.5%
|
$122,892
$76.86 P/Share
|
|
May 05
2020
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
3,283
+10.05%
|
$249,508
$76.86 P/Share
|
|
May 05
2020
|
Michael Fleming SVP Chief Ethics & Com Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
458
-6.27%
|
$34,808
$76.86 P/Share
|
|
May 05
2020
|
Michael Fleming SVP Chief Ethics & Com Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,290
+15.01%
|
$98,040
$76.86 P/Share
|
|
May 05
2020
|
Frank Clyburn EVP & Pres ? Human Health |
SELL
Payment of exercise price or tax liability
|
Direct |
1,848
-2.24%
|
$140,448
$76.86 P/Share
|
|
May 05
2020
|
Frank Clyburn EVP & Pres ? Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
3,752
+4.34%
|
$285,152
$76.86 P/Share
|
|
May 04
2020
|
Jennifer Zachary EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,843
-29.96%
|
$218,911
$77.67 P/Share
|
|
May 04
2020
|
Jennifer Zachary EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,772
+37.82%
|
$444,444
$77.67 P/Share
|
|
May 04
2020
|
Michael Nally EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
565
-5.5%
|
$43,505
$77.67 P/Share
|
|
May 04
2020
|
Michael Nally EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,298
+11.22%
|
$99,946
$77.67 P/Share
|
|
May 04
2020
|
Rita A Karachun Sr. VP Fince-Global Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
597
-2.23%
|
$45,969
$77.67 P/Share
|